Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables growth accelerates

Q1 FY2026 accounts payables of $549K rose 241.0% year over year, ahead of the -192.7% change in trailing-twelve-month accounts payables.

Context

  • Accounts payables amounted to 64.3% of revenue in FY2025, down 4.9 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +241.0% holds above the trailing-twelve-month pace of -192.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$549K+125.4% QoQ
Last fiscal yearDec 2025
-$1.05M-247.7% YoY
LTMMar 2026
-$662K-192.7% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+241.0%——
1 year-247.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1.05M) USD
Year-over-year change
-247.7%

Accounts Payables vs competitors

How RANI compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -192.7% is the 6th highest of 8, against a peer median of +55.9%.
  • Accounts payables amounts to 20.9% of revenue for RANI, versus a peer median of 27.4%.
RANI Competitors
Accounts Payables for RANI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$7.58M USD+55.9%—425.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.21M USD+1496.2%+17.8%992.0%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 2026$4.81M USD+299.9%—27.4%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$3.83M USD-230.5%——
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$3.53M USD-272.3%+109.1%—
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$3.51M USD+170.1%-40.6%10.2%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$662K USD-192.7%—20.9%
MOLNMolecular Partners AGLTM Mar 2026CHF 504.13K CHF-32.5%——
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
Peer median (excluding RANI) —+55.9%+17.8%27.4%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(8.33M)(63.34M)(33.97M)(56.58M)(29.67M)
Depreciation & Amortization497K548K822K1.03M900K
Deferred Income Tax00000
Stock-Based Compensation22.6M15.78M19.01M16.03M11.8M
Change in Working Capital(3.43M)509K(2.14M)(544K)6.96M
Accounts Receivables000(428K)(1.61M)
Inventory00000
Accounts Payables543K163K(595K)711K(1.05M)
Other Working Capital(3.97M)346K(1.55M)(827K)9.62M
Other Non-Cash Items(43.58M)(10K)(34.96M)4.57M(8.7M)
Operating Cash Flow(32.25M)(46.52M)(51.24M)(35.5M)(18.71M)
Capital Expenditures(506K)(1.62M)(1.23M)(268K)(88K)
Acquisitions (Net)0(851K)000
Purchases of Investments0(73.82M)(73.26M)(58.72M)(33.97M)
Sales of Investments03M104.35M77.55M26.75M
Other Investing Activities0851K01.25M278K
Investing Cash Flow(506K)(72.44M)29.86M19.81M(7.03M)
Debt Repayment(2.85M)29.57M0(5M)(20.72M)
Common Stock Issued73.65M317K395K18.63M61.08M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities26K(886K)(162K)(47K)(59K)
Financing Cash Flow77.15M29.01M233K13.59M40.3M
Effect of Forex Changes00000
Net Change in Cash44.4M(89.95M)(21.14M)(2.1M)14.56M
Free Cash Flow(32.75M)(48.13M)(52.47M)(35.76M)(18.8M)

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.